Inhibition of cytochrome P4502C9 activity in vitro by 5-hydroxytryptamine and adrenaline

被引:15
|
作者
Gervasini, G
Martínez, C
Agúndez, JAG
García-Gamito, FJ
Benítez, J
机构
[1] Univ Extremadura, Fac Med, Dept Farmacol, E-06071 Badajoz, Spain
[2] INSALUD Hosp Merida, Serv Gen Surg, Badajoz, Spain
来源
PHARMACOGENETICS | 2001年 / 11卷 / 01期
关键词
diclofenac; CYP2C9; microsomes;
D O I
10.1097/00008571-200102000-00004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In the present study, the occurrence of a modulatory effect of 14 neurotransmitters, precursors and metabolites on the cytochrome P450 2C9 (CYP2C9) enzyme activity, as determined by diclofenac 4-hydroxylation, was studied in human liver microsomes. Two indoleamines, 5-hydroxytryptamine (5-HT) and adrenaline, showed a non-competitive-type inhibitory effect of approximately 90% of the diclofenac 4-hydroxylase activity, with K-i values of 63.5 (0.7 and 156 (89.3 muM, respectively. The rest of substances analysed were weak inhibitors or had no inhibitory effect, CYP2C subfamily is present in human brain, although CYP2C9 isozyme has not yet been identified in this tissue, and CYP2C9 is involved in the metabolism of psychoactive drugs. Therefore, the fact that endogenous compounds could modulate the CYP2C9 activity, suggests that an hypothetical local activity of brain CYP2C9 might be susceptible to regulatory mechanisms. The possible clinical implications of this modulation are discussed. Pharmacogenetics 11:29-37 (C) Lippincott Williams & Wilkins.
引用
收藏
页码:29 / 37
页数:9
相关论文
共 50 条
  • [41] Comparison of cytochrome P4502C9 genotyping methods and implications for the clinical laboratory
    Aquilante, CL
    Lobmeyer, MT
    Langaee, TY
    Johnson, JA
    PHARMACOTHERAPY, 2004, 24 (06): : 720 - 726
  • [42] Role of conserved Asp293 of cytochrome P4502C9 in substrate recognition and catalytic activity
    Flanagan, JU
    McLaughlin, LA
    Paine, MJI
    Sutcliffe, MJ
    Roberts, GCK
    Wolf, CR
    BIOCHEMICAL JOURNAL, 2003, 370 : 921 - 926
  • [43] Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein
    Yasar, Ü
    Annas, A
    Svensson, JO
    Lazorova, L
    Artursson, P
    Al-Shurbaji, A
    XENOBIOTICA, 2005, 35 (08) : 785 - 796
  • [44] Modeling and synthesis of novel tight-binding inhibitors of cytochrome P4502C9
    Peng, Chi-Chi
    Rushmore, Tom
    Crouch, Gregory J.
    Jones, Jeffrey P.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (07) : 4064 - 4074
  • [45] Metabolites of cytochrome P4502C9 are not essential for the regulation of coronary vasomotor tone in swine
    Merkus, D
    Sorop, O
    Houweling, B
    Duncker, DJ
    FASEB JOURNAL, 2006, 20 (05): : A1399 - A1399
  • [46] Warfarin and cytochrome P4502C9 genotype: possible ethnic variation in warfarin sensitivity
    Kealey, Canel
    Chen, Zhen
    Christie, Jason
    Thorn, Caroline F.
    Whitehead, Alexander S.
    Price, Maureen
    Samaha, Frederick F.
    Kimmel, Stephen E.
    PHARMACOGENOMICS, 2007, 8 (03) : 217 - 225
  • [47] Cytochrome P4502C9 plays an important role in the regulation of exercise hyperemia in humans
    Hillig, T
    Krustrup, P
    Fleming, I
    Osada, T
    Saltin, B
    Hellsten, Y
    FASEB JOURNAL, 2002, 16 (05): : A1140 - A1140
  • [48] Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P4502C9
    Gannett, PM
    Kabulski, J
    Perez, FA
    Liu, ZY
    Lederman, D
    Locuson, CW
    Ayscue, RR
    Thomsen, NM
    Tracy, TS
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (26) : 8374 - 8375
  • [49] Cytochrome P4502C9 induces cycloxygenase-2 expression in endothelial cells
    Michaelis, UR
    Fisslthaler, B
    Fleming, I
    Busse, R
    EUROPEAN HEART JOURNAL, 2003, 24 : 13 - 13
  • [50] The impact of CYP2C9 genetics and oral contraceptives on cytochrome P4502C9 phenotype
    Sandberg, M
    Johansson, I
    Christensen, M
    Rane, A
    Eliasson, E
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (05) : 484 - 489